Is the biotech boom starting to fade? The roaring ‘20s starts to look a little fatigued. Plus: Top 5 deals, IPOs, pacts of Q3
Biotech deal cash continued to gush through Q3, but a careful look at the details in aggregate suggests that the rosy tint to the biotech boom has started to lose some of its color.
Once again, deal master Chris Dokomajilar at DealForma has crunched the numbers on all the gauges we use to assess the performance of the biotech sector. And there’s been a distinct cooling of overall activity, particularly around IPOs and venture cash infusions.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters